Veru, Inc.
(NASDAQ : VERU)

( )
VERU After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.40%160.110.7%$1208.66m
PFEPfizer Inc. 0.08%37.190.9%$1005.03m
MRKMerck & Co., Inc. 0.00%76.430.7%$966.72m
ABBVAbbVie, Inc. -0.86%106.001.9%$820.34m
BMYBristol-Myers Squibb Co. 0.41%63.841.0%$725.84m
LLYEli Lilly & Co. 0.33%183.131.1%$599.57m
AZNAstraZeneca Plc 1.32%49.841.2%$440.69m
GSKGlaxoSmithKline Plc 0.24%36.130.2%$179.07m
RPRXRoyalty Pharma Plc 1.67%42.120.2%$163.20m
NVSNovartis AG 0.16%86.750.2%$149.07m
VTRSViatris, Inc. 1.85%13.210.0%$129.35m
RGENRepligen Corp. -3.56%205.296.8%$87.69m
CVACCureVac NV 7.28%102.610.0%$83.02m
ATNF180 Life Sciences Corp. -3.06%10.460.0%$62.67m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.94%74.920.0%$61.28m

Company Profile

Veru, Inc. is an oncology biopharmaceutical company engaged in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects; and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.